Marvel Biosciences Announces Proposed Convertible Debenture Offering
Rhea-AI Summary
Marvel Biosciences (OTC: MBCOF) announced a non-brokered private placement of unsecured convertible debentures up to $500,000 to fund drug formulation, toxicology studies and working capital. The Debentures carry 12% annual interest, mature December 31, 2027, and convert at $0.12 per share, subject to TSX Venture Exchange approval.
Interest may be paid in cash or shares; the company can force conversion if the 10-day VWAP reaches $0.60 for 10 consecutive trading days. Securities will have a standard four-month-and-one-day hold period.
AI-generated analysis. Not financial advice.
Positive
- Raises up to $500,000 to finance drug formulation and toxicology
- 12% annual interest provides lender yield
- Convertible feature offers potential equity funding at $0.12 per share
Negative
- Debentures are unsecured, exposing lenders to higher credit risk
- Interest payable in shares may cause share dilution
- Company can force conversion at $0.60, altering shareholder mix
News Market Reaction – MBCOF
On the day this news was published, MBCOF declined 18.96%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures ("Debentures") in the principal amount of up to
The Debentures will bear interest at the rate of twelve percent (
All securities issued in connection with the Private Placement will be subject to a hold period that will expire four months and one day from the date of issuance. The net proceeds from the Private Placement will be used for drug formulation, toxicology studies and for general working capital purposes.
No Common Shares shall be issued by the Company on the conversion of the Debenture if, as a result of the issuance of such Common Shares, the holder of the Debenture, together with any person acting jointly or in concert with the holder including for greater certainty any of its affiliates, would in the aggregate beneficially own, or exercise control or direction over (or a combination thereof), whether direct or indirect, ten percent (
The Company will not pay any commission, finder's fee, or similar payment in connection with the Offering.
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB 204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President, and Chief Science Officer
Tel: 403 770 2469
Website: www.marvelbiotechnology.com | Twitter/X | LinkedIn
Neither the TSX Venture Exchange nor its Regulation Services Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This press release contains certain statements which constitute forward-looking statements or information ("forward-looking statements"), including statements regarding Marvel's business, the Offering, including the use of proceeds of the Private Placement. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Marvel's control, including the impact of general economic conditions, the current share price of Marvel's common shares, TSX Venture acceptance and market acceptance of the Private Placement, industry conditions, currency fluctuations, the lack of availability of qualified personnel or management, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Marvel believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking information. As such, readers are cautioned not to place undue reliance on the forward -looking information, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this document are made as of the date of this document and, except as required by applicable law, Marvel does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291673